|Bid||1.9600 x 1000|
|Ask||2.1400 x 1100|
|Day's Range||0.1500 - 0.2373|
|52 Week Range||0.1500 - 4.7430|
|Beta (5Y Monthly)||0.33|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NEW YORK, December 01, 2021--PAVmed subsidiary Lucid Diagnostics launches EsoGuard telemedicine program in partnership with UpScriptHealth.
NEW YORK, November 17, 2021--Lucid Diagnostics to present at Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum.
NEW YORK, November 16, 2021--PAVmed and Lucid provide business update and preliminary third quarter 2021 financial results.